Literature DB >> 29721625

[Acute life-threatening drug reactions of the skin].

M Mockenhaupt1.   

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acutely occurring, unpredictable, often life-threatening reactions that are a huge challenge in clinical practice. They are characterized by extensive blistering of skin and mucosa and are considered as one disease entity of different severity. Thus, they are summarized as SJS/TEN or EN (for epidermal or epithelial necrolysis). The diagnosis can be confirmed through synopsis of clinical pattern and histopathological findings. To identify the inducing factors, it is crucial to obtain a detailed and thorough medication and infection history. Based on the results of large epidemiological studies, potentially inducing drugs can be narrowed down even in cases of multimedication and underlying diseases. Agents with a high risk for SJS/TEN are allopurinol, antibacterial sulfonamides, non-steroidal anti-inflammatory drugs of the oxicam-type, various antiepileptics and nevirapine. They alone explain more than half of the cases of SJS/TEN. Typically, the reaction occurs during the first continuous use of the medication, while the beginning of use most often is one to four weeks prior to reaction onset. However, a drug is not always the cause of the reaction, but in approximately 70-75% of the cases very likely. In other cases infections may be potential causes. If certain medications are thought to be the inducing factors, they should be withdrawn without delay. In addition, symptomatic treatment should be initiated. In case of progression, an additional immunomodulating therapy should be considered. In this respect, systematic reviews have shown best results for cyclosporine A and systemic steroids.

Entities:  

Keywords:  Prognosis; Risk factors; Stevens-Johnson syndrome; Therapy; Toxic epidermal necrolysis

Mesh:

Substances:

Year:  2018        PMID: 29721625     DOI: 10.1007/s00105-018-4176-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  41 in total

1.  Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry.

Authors:  B Rzany; M Mockenhaupt; S Baur; W Schröder; U Stocker; J Mueller; N Holländer; R Bruppacher; E Schöpf
Journal:  J Clin Epidemiol       Date:  1996-07       Impact factor: 6.437

2.  Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Jui-Yung Yang; Shih-Chi Su; Shien-Ping Huang; Chun-Yu Wei; See-Wen Chin; Chien-Chun Chiou; Sung-Chao Chu; Hsin-Chun Ho; Chih-Hsun Yang; Chi-Fang Lu; Jer-Yuarn Wu; You-Di Liao; Yuan-Tsong Chen
Journal:  Nat Med       Date:  2008-11-23       Impact factor: 53.440

3.  Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk?

Authors:  Cynthia Haddad; Alexis Sidoroff; Sylvia H Kardaun; Maja Mockenhaupt; Daniel Creamer; Ariane Dunant; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

4.  Epidemiology of staphylococcal scalded skin syndrome in Germany.

Authors:  Maja Mockenhaupt; Marco Idzko; Martine Grosber; Erwin Schöpf; Johannes Norgauer
Journal:  J Invest Dermatol       Date:  2005-04       Impact factor: 8.551

Review 5.  Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes.

Authors:  Manuel Florian Struck; Peter Hilbert; Maja Mockenhaupt; Beate Reichelt; Michael Steen
Journal:  Intensive Care Med       Date:  2009-09-29       Impact factor: 17.440

Review 6.  [Severe skin reactions due to new medications].

Authors:  M Mockenhaupt; M Paulmann
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

7.  Immune pathomechanism of drug hypersensitivity reactions.

Authors:  Werner J Pichler; Dean J Naisbitt; B Kevin Park
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

8.  Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors:  J P Fagot; M Mockenhaupt; J N Bouwes-Bavinck; L Naldi; C Viboud; J C Roujeau
Journal:  AIDS       Date:  2001-09-28       Impact factor: 4.177

Review 9.  Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome.

Authors:  Pierre-Dominique Ghislain; Jean-Claude Roujeau
Journal:  Dermatol Online J       Date:  2002-06

10.  Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.

Authors:  Ariane Auquier-Dunant; Maja Mockenhaupt; Luigi Naldi; Osvaldo Correia; Werner Schröder; Jean-Claude Roujeau
Journal:  Arch Dermatol       Date:  2002-08
View more
  1 in total

1.  [Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].

Authors:  Argyrios Chronopoulos; Maja Mockenhaupt; Uwe Pleyer
Journal:  Ophthalmologe       Date:  2021-03-16       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.